entertainment -WSS

entertainment

author：hotspot 2025-10-01 00:46:15 - browse：11652

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： WuXi Biologics beefs up its lobbying operation

focus

WSS

HHS suspends federal funding for EcoHealth Alliance

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Ripples from Flovent's discontinuation is killing children with asthma

Hottest summer in 2,000 years puts focus on extreme heat, health

HHS suspends federal funding for EcoHealth Alliance

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

knowledge

entertainment

entertainment

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Drug repurposing or repositioning? The language matters

Oak Street deal isn't the answer to health care's woes

Tori Bowie and the unacceptable rates of Black maternal death

WuXi Biologics execs register to lobby as Congress comes for the company

BioMarin wins approval for gene therapy to treat hemophilia A

ALS treatment from Biogen, Ionis fails in study

Malaria cases in Florida and Texas: Here’s what you need to know

The aspartame in Diet Coke probably isn’t giving you cancer

explore

Fertility clinic egg and embryo storage is a disaster

Fertility clinic egg and embryo storage is a disaster

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Boston hospital trains restaurant workers on naloxone for overdoses

WuXi Biologics beefs up its lobbying operation

Abbott's new stent may help patients with peripheral artery disease

focus

focus

focus

knowledge